NCT01724814View on ClinicalTrials.gov

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

December 20, 2012

Primary Completion Date

July 1, 2014

Study Completion Date

July 1, 2014

Conditions
HealthyType 1 Diabetes MellitusType 2 Diabetes Mellitus
Interventions
DRUG

HM12460A

Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A

DRUG

Placebo

Singe dose SC administration of Placebo

Trial Locations (1)

91911

Hanmi pharma, Chula Vista

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT01724814 - A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A | Biotech Hunter | Biotech Hunter